Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 29:7:F1000 Faculty Rev-1347.
doi: 10.12688/f1000research.14822.1. eCollection 2018.

Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now?

Zoi Dorothea Pana  1 , Theoklis Zaoutis  2
Affiliations
Review

Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now?

Zoi Dorothea Pana et al. F1000Res. .

Abstract

The spread of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-PE) has dramatically increased worldwide, and this "evolving crisis" is currently regarded as one of the most important public health threats. The growing problem of ESBL-PE antimicrobial resistance seems to have a dual face between "Scylla and Charybdis": on one hand the potential for rapid spread and dissemination of resistance mechanisms and on the other hand the injudicious overuse of antimicrobial agents and the inadequate infection control measures, especially in the health-care setting. Given the World Health Organization's warning against a "post antibiotic era", health-care providers are at a critical standpoint to find a "balance" between safe and effective ESBL-PE treatment and avoidance of inducing further resistance mechanisms. The aim of the review is to summarize the updated published knowledge in an attempt to answer basic everyday clinical questions on how to proceed to effective and the best ESBL-PE treatment options based on the existing published data.

Keywords: ESBL treatment; Enterobacteriaceae; lactamase producers.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

References

    1. Morrissey I, Hackel M, Badal R, et al. : A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel). 2013;6(11):1335–46. 10.3390/ph6111335 - DOI - PMC - PubMed
    1. Flokas ME, Karanika S, Alevizakos M, et al. : Prevalence of ESBL-Producing Enterobacteriaceae in Pediatric Bloodstream Infections: A Systematic Review and Meta-Analysis. PLoS One. 2017;12(1):e0171216. 10.1371/journal.pone.0171216 - DOI - PMC - PubMed

    2. F1000 Recommendation

    1. Lee SY, Kotapati S, Kuti JL, et al. : Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol. 2006;27(11):1226–32. 10.1086/507962 - DOI - PubMed

    2. F1000 Recommendation

    1. Maslikowska JA, Walker SA, Elligsen M, et al. : Impact of infection with extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella species on outcome and hospitalization costs. J Hosp Infect. 2016;92(1):33–41. 10.1016/j.jhin.2015.10.001 - DOI - PubMed

    2. F1000 Recommendation

    1. Biehl LM, Schmidt-Hieber M, Liss B, et al. : Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients - Review of the literature from a clinical perspective. Crit Rev Microbiol. 2016;42(1):1–16. 10.3109/1040841X.2013.875515 - DOI - PubMed

    2. F1000 Recommendation

MeSH terms